Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand

• Main Authors: Chotpitayasunondh T., Pruekprasert P., Puthanakit T., Pancharoen C., Tangsathapornpong A., Oberdorfer P., Kosalaraksa P., Prommalikit O., Tangkittithaworn S., Kerdpanich P., Techasaensiri C., Korejwo J., Chuenkitmongkol S., Houillon G.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85006966243&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/40843
• Institution: Chiang Mai University

© 2016 The Authors Background Japanese encephalitis is a mosquito-borne viral disease endemic in most countries in Asia. A recombinant live, attenuated Japanese encephalitis virus vaccine, JE-CV, is licensed in 14 countries, including Thailand, for the prevention of Japanese encephalitis in adults a...